Bernard Chevalier

Showing 1-20 of 39 articles

Optimal dual antiplatelet therapy duration for bioresorbable scaffolds: an individual patient data pooled analysis of the ABSORB trials

Azzalini L, Ellis S, Kereiakes D, Kimura T, Gao R, Onuma Y, Chevalier B, Dressler O, Crowley A, Zhou Z, Redfors B, Serruys P, Stone G

December 17, 2021 | 10.4244/EIJ-D-21-00263

Clinical outcomes of the proximal optimisation technique (POT) in bifurcation stenting

Chevalier B, Mamas M, Hovasse T, Rashid M, Gómez-Hospital J, Pan M, Witkowski A, Crowley J, Aminian A, McDonald J, Beygui F, Fernandez Portales J, Roguin A, Stankovic G

December 3, 2021 | 10.4244/EIJ-D-20-01393

Proximal optimisation technique versus final kissing balloon inflation in coronary bifurcation lesions: the randomised, multicentre PROPOT trial

Watanabe Y, Murasato Y, Yamawaki M, Kinoshita Y, Okubo M, Yumoto K, Masuda N, Otake H, Aoki J, Nakazawa G, Numasawa Y, Ito T, Shite J, Okamura T, Takagi K, Kozuma K, Lefèvre T, Chevalier B, Louvard Y, Suzuki N, Kozuma K

October 20, 2021 | 10.4244/EIJ-D-20-01386

Coronary interventions

Bioresorbable scaffolds versus everolimus-eluting metallic stents: five-year clinical outcomes of the randomised ABSORB II trial

Onuma Y, Chevalier B, Ono M, Cequier A, Dudek D, Haude M, Carrié D, Sabaté M, Windecker S, Rapoza R, West N, Reith S, de Sousa Almeida M, Campo G, Iniguez-Romo A, Serruys P

December 4, 2020 | 10.4244/EIJ-D-20-00024

Coronary interventions

Bioresorbable vascular scaffold versus metallic drug-eluting stent in patients at high risk of restenosis: the COMPARE-ABSORB randomised clinical trial

Smits P, Chang C, Chevalier B, West N, Gori T, Barbato E, Tarantini G, Kocka V, Achenbach S, Dudek D, Escaned J, Wlodarczak A, Abdel-Wahab M, Esposito G, Tijssen J, Morice M, Onuma Y, van Geuns R

October 23, 2020 | 10.4244/EIJ-D-19-01079

Impact of coronary lesion complexity in percutaneous coronary intervention: one-year outcomes from the large, multicentre e-Ultimaster registry

Mohamed M, Polad J, Hildick-Smith D, Bizeau O, Baisebenov R, Roffi M, Iniguez-Romo A, Chevalier B, von Birgelen C, Roguin A, Aminian A, Angioi M, Mamas M

September 18, 2020 | 10.4244/EIJ-D-20-00361

Coronary interventions

Acute and long-term relocation of minimal lumen area after bioresorbable scaffold or metallic stent implantation

Katagiri Y, Serruys P, Tenekecioglu E, Asano T, Collet C, Miyazaki Y, Katsikis A, Piek J, Wykrzykowska J, Chevalier B, Mintz GS, Stone G, Onuma Y

September 20, 2019 | 10.4244/EIJ-D-18-00422

Coronary interventions

Relation between bioresorbable scaffold sizing using QCA-Dmax and long-term clinical outcomes in 1,232 patients from three study cohorts (ABSORB Cohort B, ABSORB EXTEND, and ABSORB II)

Katagiri Y, Onuma Y, Asano T, Chichareon P, Collet C, Miyazaki Y, Piek J, Wykrzykowska J, Abizaid A, Ormiston J, Chevalier B, Serruys P

October 12, 2018 | 10.4244/EIJ-D-18-00301

Polymer-free drug-coated stents: workhorse or “niche horse”?

Urban P, Chevalier B

September 20, 2018 | 10.4244/EIJV14I7A128

Stents and scaffolds

Four-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II Trial)

Chevalier B, Cequier A, Dudek D, Haude M, Carrié D, Sabaté M, Windecker S, Reith S, de Sousa Almeida M, Campo G, Iñiguez A, Onuma Y, Serruys P

January 19, 2018 | 10.4244/EIJ-D-17-00873

Coronary interventions

Does geographical variability influence five-year MACCE rates in the multicentre SYNTAX revascularisation trial?

Roy A, Chevalier B, Lefèvre T, Louvard Y, Segurado R, Sawaya F, Spaziano M, Neylon A, Serruys P, Dawkins K, Kappetein A, Mohr F, Colombo A, Feldman T, Morice M

September 20, 2017 | 10.4244/EIJ-D-16-00991

Coronary interventions

Chronic total coronary occlusion treated by percutaneous coronary intervention: long-term outcome in patients with and without diabetes

Sanguineti F, Garot P, O’Connor S, Watanabe Y, Spaziano M, Lefèvre T, Hovasse T, Benamer H, Unterseeh T, Chevalier B, Morice M, Louvard Y

February 3, 2017 | 10.4244/EIJ-D-15-00278

Coronary interventions

Randomised comparison of a bioresorbable everolimus-eluting scaffold with a metallic everolimus-eluting stent for ischaemic heart disease caused by de novo native coronary artery lesions: the 2-year clinical outcomes of the ABSORB II trial

Chevalier B, Onuma Y, Van Boven A, Piek J, Sabaté M, Helqvist S, Baumbach A, Smits P, Kumar R, Wasungu L, Serruys P

October 20, 2016 | 10.4244/EIJY16M08_01

Interventions for valvular disease

Patient-specific image-based computer simulation for the prediction of valve morphology and calcium displacement after TAVI with the Medtronic CoreValve and the Edwards SAPIEN valve

Schultz C, Rodriguez-Olivares R, Bosmans J, Lefèvre T, De Santis G, Bruining N, Collas V, Dezutter T, Bosmans B, Rahhab Z, Faquir N, Watanabe Y, Segers P, Verhegghe B, Chevalier B, Van Mieghem N, De Beule M, Mortier P, de Jaegere P

January 20, 2016 | 10.4244/EIJV11I9A212

Bioresorbable vascular scaffold treatment induces the formation of neointimal cap that seals the underlying plaque without compromising the luminal dimensions: a concept based on serial optical coherence tomography data

Bourantas C, Serruys P, Nakatani S, Zhang Y-J, Farooq V, Diletti R, Ligthart J, Sheehy A, van Geuns R, McClean D, Chevalier B, Windecker S, Koolen J, Ormiston J, Whitbourn R, Rapoza R, Veldhof S, Onuma Y, Garcia-Garcia H

November 20, 2015 | 10.4244/EIJY14M10_06

Five-year clinical outcome of the Nobori drug-eluting coronary stent system in the treatment of patients with coronary artery disease: final results of the NOBORI 1 trial

Chevalier B, Wijns W, Silber S, Garcia E, Serra A, Paunovic D, Serruys P

September 22, 2015 | 10.4244/EIJY14M12_13

Impact of post-dilation on the acute and one-year clinical outcomes of a large cohort of patients treated solely with the Absorb Bioresorbable Vascular Scaffold

Costa Jr J, Abizaid A, Bartorelli A, Whitbourn R, van Geuns R, Chevalier B, Perin M, Seth A, Botelho R, Serruys P

June 19, 2015 | 10.4244/EIJY15M05_06

Coronary interventions

The future of BRS in bifurcations

Kraak R, Grundeken M.J, Onuma Y, Tu S, Wykrzykowska J, Chevalier B, Ormiston J, Serruys P

May 19, 2015 | 10.4244/EIJV11SVA45

The ABSORB EXTEND study: preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled

Abizaid A, Costa Jr J, Bartorelli A, Whitbourn R, van Geuns R, Chevalier B, Patel T, Seth A, Stuteville M, Dorange C, Cheong W-F, Sudhir K, Serruys P

April 20, 2015 | 10.4244/EIJV10I12A243

Circumferential distribution of the neointima at six-month and two-year follow-up after a bioresorbable vascular scaffold implantation: a substudy of the ABSORB Cohort B Clinical Trial

Bourantas C, Farooq V, Zhang Y-J, Muramatsu T, Gogas B, Thuesen L, McClean D, Chevalier B, Windecker S, Koolen J, Ormiston J, Whitbourn R, Dorange C, Rapoza R, Onuma Y, Garcia-Garcia H, Serruys P

March 20, 2015 | 10.4244/EIJY14M04_11

1
2

Latest news

Three-year TAVI outcomes for BAV vs TAV

FREE ARTICLE - Dao Zhou et al.

January 20, 2022

Percutaneous management of left ventricular assist device outflow graft obstruction

FREE ARTICLE - Aleksandra Gasecka et al.

January 19, 2022

EuroCTO Club Consensus on Dual Lumen Microcatheters for CTO Recanalisation; Predicting Radial Crossover in ACS, the MATRIX score; DAPT duration for BRS; and more…

December 17, 2021

Lipid-rich plaque density and LDL-C in statin-treated vs statin-naïve patients

FREE ARTICLE - Rebecca Torguson et al.

January 17, 2022

Redo transcatheter mitral valve replacement in mitral annular calcification

FREE ARTICLE - Jennifer Jdaidani et al

January 13, 2022

TAVI vs SAVR in bicuspid aortic valve stenosis

FREE ARTICLE - Monil Majmundar et al.

January 12, 2022

Management of MR patients undergoing TMVI screening

FREE ARTICLE - Sebastian Ludwig et al.

January 7, 2022

Valvular disease